Amid rising global cancer rates and a shortage of pathology staff, Taiwan-based AetherAI says its FDA- and IVDR-certified digital pathology platform could ease diagnostic bottlenecks worldwide by enabling integrated AI tools and automated workflows,...
The article requires paid subscription. Subscribe Now



